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Abstract: 
Encapsulating peritoneal sclerosis (EPS) is a potentially devastating complication of peritoneal dialysis 
(PD). Diagnosis is often delayed due to the lack of effective and accurate diagnostic tools.  We 
therefore examined peritoneal effluent for potential biomarkers that could predict or confirm the 
diagnosis of EPS and would be valuable in stratifying atrisk patients, and driving appropriate 
interventions. Using prospectively collected samples from the Global Fluid Study and a cohort of 
Greek PD patients, we utilized 2D SDSPAGE/ MS and iTRAQ to identify changes in the peritoneal 
effluent proteome from patients diagnosed with EPS and controls matched for treatment exposure. We 
employed a combinatorial peptide ligand library to compress the dynamic range of protein 
concentrations, to aid identification of lowabundance proteins. In patients with stable membrane 
function, fibrinogen chain and heparan sulphate proteoglycan core protein progressively 
increased over time on PD. In patients who developed EPS, collagen1(I), actin and Complement 
factors B and I were elevated up to five years prior to diagnosis. Orosomucoid1 and a2HS
glycoprotein chainB were elevated about one year before diagnosis, while apolipoprotein AIV and 
1antitrypsin were decreased compared to controls. Dynamic range compression resulted in an 
increased number of proteins detected with improved resolution of protein spots, compared to the full 
fluid proteome. Intelectin1, dermatopontin, gelsolin and retinol binding protein4 were elevated in 
proteomemined samples from patients with EPS compared to patients that had just commenced 
peritoneal dialysis. Thus, prospective analysis of peritoneal effluent uncovered proteins indicative of 
inflammatory and profibrotic injury worthy of further evaluation as diagnostic/prognostic markers.  
Keywords: peritoneal dialysis, encapsulating peritoneal sclerosis, biomarkers, proteomics 
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Introduction: 
 Encapsulating peritoneal sclerosis (EPS) is a rare complication of peritoneal dialysis (PD) 
resulting in significant morbidity and mortality(1).  Overall reported lifetime risk ranges from 0.54%(2) to 
3.3%(3).  Incidence increases with the duration of PD treatment (46), ranging from 0.7%(4) to 8.1%(5) at 5 
years and from 2.1%(4) to 19.4%(6) at 8 years.  The development of EPS has been associated with 
numerous factors including glucose load, rapid solute transport status and intraperitoneal 
inflammation, requirement for icodextrin use, ultrafiltration failure associated with reduced free water 
transport, modality change, young age and genetic predisposition (714). 
The pathogenesis of EPS remains poorly defined but multiple hits appear to be required in 
patients predisposed to peritoneal injury by uremia and dialysis solution exposure.(15)  Although 
episodic infection, epithelialtomesenchymal transition (EMT)(16) and the involvement of uncontrolled 
inflammatory cascades (TGFbeta, VEGF etc.)(1720) may be contributory factors, to date no single 
definitive pathway has been identified.   
Clinical signs of EPS include persistent or recurrent bowel dysfunction and nutritional 
impairment(1).  Diagnosis is confirmed at laparotomy or on PET/CT imaging(21), but the rarity of the 
disorder, variable presentation and lack of screening tools frequently lead to delayed diagnosis.  
Peritoneal dialysis effluent (PDE) biomarkers that could predict the onset or confirm the diagnosis of 
EPS would allow the development of prognostic tools and, potentially, the identification of future 
therapeutic targets.  Proteomics technologies provide us with powerful tools for an indepth exploration 
of the PDE proteome, yet relevant studies have been few and to date preliminary (2238). 
In the present study, we have used an optimised proteomics approach to detect prospective 
changes in the PDE proteome of clinically welldescribed patients from the Global Fluid Study (GFS) 
cohort who subsequently developed EPS.  Controls were patients from the same cohort with stable 
membrane function who did not subsequently develop EPS.  EPS and stable patients were matched 
for time on treatment or time to developing EPS/stopping PD.  The aim of this study was to identify 
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proteins in the drained PD effluent whose measurement might predict the onset of EPS.  Further 
analysis, using a cohort of Greek PD patients, utilized methods to allow detection of lower abundance 
proteins by using a combinatorial peptide ligand library (CPLL).  Based on these experiments, our data 
identifies proteins whose expression changes in EPS patients and in some cases are expressed in 
PDE significantly in advance of clinical diagnosis.  These data support growing evidence that EPS is 
preceded by inflammatory and fibrotic peritoneal injury and would seem worthy of further exploration 
as candidate markers of EPS diagnosis and monitoring.  
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Results: 
Determination of protein changes with time on PD in patients with stable peritoneal membrane 
function
 To ascertain the timecourse of changes in the levels of proteins in PDE, samples from 5 
patients with at least 10 sequentially collected effluent samples spanning a period of >4 years on PD, 
were analysed by 2D PAGE.  Over 800 protein spots were consistently detectable in all samples when 
analysed by PDQuest.  The majority of these proteins were relatively constant in expression providing 
confidence of the validity and fidelity of the methodology selected (Figure 1).  PDQuest identified 
approximately 25 spots that either increased (x2) or were reduced (x2) in intensity in a progressive 
manner with dialysis duration.  Of these, however, only 2 spots were consistently changed in greater 
than 4 out of the 5 patient samples evaluated.  Mass spectrometry identified these proteins as 
fibrinogen chain (Figure 2a) and HeparanSulphate Proteoglycan (HSPG) (Figure 2b).  Based on 
spot intensities, fibrinogen chain began to b  elevated after approximately 30% of total dialysis 
duration before plateauing while HSPG levels showed a progressive increase over the entire duration 
of PD treatment.
Determination of protein changes in patients that developed EPS  
A. 2D SDS PGE MS proteomics 
 To determine which proteins were changing in patients who were ultimately diagnosed with 
EPS, 6 UK patients from the GFS, who had EPS diagnosis confirmed by CT scan, and who had ³4 
sequential samples prior to this diagnosis were selected.  Each of these patients was matched to a 
patient from the same centre according to the following criteria: equal exposure to PD treatment, 
comparable sampling points from the time of initiation of PD, stable membrane function and lack of 
any evidence indicative of EPS (see Supplemental Table 1 for time point matching details).  The 
Dodeca gel system that was used for the study runs a maximum of 12 gels, so 6 EPS gels and 6 
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matched control sample gels was the maximum comparison that could be performed in a single 
experiment.  Twenty four spots were identified in all the EPS patients as being differentially altered 
over time compared to the matched patients control samples. Of these, 2 spots were identified as 
being altered consistently in all of the 6 EPS patients in comparison to the control patients.  Collagen
1(I) became elevated in EPS patients (Figure 3a) typically after 30% of total dialysis duration, while 
actin (Figure 3b) was frequently elevated very early (1241043 days) and remained elevated 
throughout the entire duration of PD (maximum duration was 2868 days) until EPS was diagnosed 
clinically.  In 5 out of the 6 EPS patients, changes in spots subsequently identified as complement 
factors B and factor I were seen (Figure 4). The complement factor B spot was either not present or 
barely detectable in matched patients with stable membrane function, but was elevated (in some 
patients up to 6 years before EPS was diagnosed) and remained elevated (above matched control 
levels) in those patients who were subsequently diagnosed with EPS.  The Complement factor I spot 
was present in both patient groups and decreased slightly with duration of PD.  It was, however, at 
consistently higher density at each time point in those who subsequently were diagnosed with EPS. 
1antitrypsin and apolipoprotein AIV spots appeared at noticeably lower intensity in 3 out of 6 EPS 
patients.
B. Isobariq tagging for relative and absolute quantification (iTRAQ) proteomics.
 2D SDSPAGE is a labourintensive approach, with analysis limited by the accuracy of spot 
mapping software that subsequently needs a high degree of manual mapping and is subject to data 
losses.  To address these issues we optimised a mass spectrometry based iTRAQ protocol for use 
with PDE samples and repeated the comparisons in one EPS and matched control sample pair.  An 8 
iTRAQ approach was used allowing comparison of 4 time points from each patient.  A limitation of 
iTRAQ is the low rate of protein detection, however 72 proteins had sufficient sequence recognition to 
allow for robust protein identification (Table 1).  Of these, by performing ratio analysis of the isobariq 
tag from each patient at each time point it was possible to identify 4 consistent trends (Figure 5). 
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Orosomucoid1 and 2 HSglycoprotein chain B were both elevated in the EPS patient approximately 
12 months prior to diagnosis, while Apolipoprotein AIV was always lower in EPS.  There was also a 
late drop in serotransferrin levels at EPS onset.
Protein mining.
 From both SDSPAGE and iTRAQ it was evident that >95% of the total protein load detected 
was highly abundant serum proteins such as albumin and IgG (Figure 6A).  This meant that <5% of 
the proteins being analysed were ones of potential interest.  To address this, a proteinmining 
approach was used employing the BioRad® ProteoMiner enriching system to reduce the dynamic 
range of abundant protein concentrations, while maintaining the relative levels of less abundant 
proteins.  In comparison to the full fluid proteome where approximately 800 spots were identified 
(many of which were related) (Figure 6A), post ProteoMiner analysis the same protein concentration 
yielded >2000 discrete protein spots that were all well resolved (Figure 6B).
Determination of lower abundance proteins changing in patients that developed EPS using 2D 
SDSPAGE/MS proteomics on samples subjected to ProteoMiner.
 Protein mining required a starting protein mass of approximately 15mg, to produce 60g of 
protein for proteomic analysis.  In the GFS cohort, sufficient individual patient PDE was not available 
for this type of analysis.  However, as part of a collaborative study with the University of Patras, 
Greece, we were able to obtain significant PDE volumes from 3 patients with suspected EPS.  These 
samples were compared to 3 prevalent patients with stable membrane function who had been on PD 
for >5 years and with 3 incident patients from the same centre.  All 9 samples were subjected to 
ProteoMiner analysis, fractionated by 2DSDS PAGE and compared using PDQuest.  From this 
analysis, three spots were detected that were elevated only in the PDE of patients with EPS.  
Intelectin1 (Figure 7a) was barely detectable in patients just starting PD or in patients who had been 
on PD for >5 years.  However, in patients with suspected EPS a strong protein spot was visible. 
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Likewise, dermatopontin (Figure 7b) was also strongly expressed in EPS patients, but was only mildly 
elevated in 1 of the 3 prevalent patients and not at all in patients starting PD.  Retinol binding protein4 
(RBP4) was also identified as increasing in EPS patients (not shown).  There were numerous 
additional spots seen but we were subsequently unable to identify them in our MS analysis.  
Patient pooling to facilitate protein mining and ITRAQ on the GFS cohort 
 To combine the benefit of proteinmining, the sequential sampling of patients in the GFS, the 
power of the iTRAQ approach and provide sufficient protein for meaningful analysis, we combined 
GFS effluent samples from several patients into 4 groups based on time on dialysis for both stable PD 
patients and for those developing EPS.  Samples were pooled in to Group 1; within 6 months of EPS 
or stopping dialysis, Group 2; 612 months prior to stopping dialysis, Group 3; 1224 months prior to 
stopping dialysis and Group 4; >24 months before cessation of dialysis.  Each pool of fluid (~18mg of 
protein, see supplemental table 2 for pool composition detail) was proteinmined using proteominer, 
iTRAQlabelled and analysed by MS as previously described (Figure 8). 
 Analysis identified >2,000 detectable proteins and sequence recognition allowed robust 
identification of 136 of these proteins.  Hierarchical cluster analysis showed a clear demarcation of 
proteins found between those who develop EPS and the controlmatched patient samples (Figure 9a). 
Heat map analysis (Figure 9b) demonstrated higher levels of many of these proteins in the EPS 
effluent samples across all time points analysed.  Subsequent analysis of the ratios of relative 
changes in individual proteins between EPS and nonEPS patients with time was disappointing, in that 
consistent progressive changes with time for individual proteins were limited compared to numerous 
ratio shifts at individual time points.  Nevertheless, the data confirmed the previously observed 
increases in intelectin1 expression and a small reduction in Apolipoprotein with both AII & Achains 
being reduced in samples from patients subsequently developing EPS.  Interestingly, despite 
numerous changes being observed at each time point only two additional proteins appeared to change 
progressively.  Multiple Haemoglobin subunits were dramatically increased within the last 12 months in 
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EPS patients despite no macroscopic evidence of blood in the PDE samples, whilst Gelsolin showed a 
progressive accumulation with time (Figure 10).  
Discussion:
The combination of uraemic milieu and chronic exposure to PD solutions induce the 
development of structural changes in the peritoneum(3940).  There is significant interest as to whether 
these histological changes can be correlated with or predicted by changes in effluent proteins 
(irrespective of source) and whether the levels of these proteins are altered with duration of PD.  Such 
protein changes, if consistent, might provide easily detectable effluent biomarkers of distinct peritoneal 
pathology or have routine prognostic value.  In the present study we chose to screen for effluent 
proteins in defined groups of PD patients using a broadbased proteomics approach.  We used 
prospectively collected PDE samples from the uniquely characterized patients in the GFS cohort to 
examine if specific proteins were identifiable and ask if any of these were specifically changed in 
patients who subsequently developed EPS.  The 16 proteins identified across all proteomics 
approaches, (which employed up to 10 patients that developed EPS, matched with 18 with stable 
function) are summarized in table 2.  Given that the function of some of these proteins is already 
known, we can hypothesise as to their potential role in EPS. 
Fibrin deposition is a feature of peritoneal fibrosis and EPS pathology(15).   Fibrin is derived from 
fibrinogen and both are involved in inflammatory processes.  In PDE fibrinogen chain increases 
during peritonitis and declines after successful treatment(28).  Our results indicate that the amount of 
fibrinogen chain in PDE begins to increase after 618 months on PD and plateaus thereafter.  As 
major histopathological changes in the dialysed peritoneum begin to manifest fully after ~2 years on 
PD(39), the pattern of fibrinogen chain elevation might reflect the evolution of processes that 
contribute to the establishment of peritoneal fibrosis.  Fibrinogen chain may thus become elevated 
as fibrogenesis is initiated and plateau when fibrosis becomes established.  Peritoneal fibrosis is also 
characterised by increased turnover of extracellular matrix (ECM).  This process might be reflected by 
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the  progressive increases of HSPGs(41) in PDE, as they are key components of basement 
membranes. 
 Using 2D SDSPAGE/MS, we observed increases in the concentrations of collagen1(I) and 
actin in the PDE of 6 patients subsequently diagnosed with EPS.  These changes were not seen in 
the matched control patients.  Elevation of collagen1(I) may reflect increased ECM turnover and the 
deposition of typeI collagen in the peritoneal tissues(42).  Expression of collagen1(I) mRNA is up
regulated in EPS patient peritoneum, while its accumulation in the submesothelial compact zone and 
EPSderived tissue has been demonstrated by immunostaining(4344).  Remodelling of actin 
cytoskeleton is a feature of EMT(45).  Early elevation of actin in PDE might be the result of its release 
from damaged peritoneal tissues(46).  Interestingly, the changes in actin are consistent with the 
observed increases seen in gelsolin in the pooled EPS cohort samples.  Gelsolin is an actinbinding 
protein that is a key regulator of actin filament assembly and disassembly and one of the most potent 
members of the actinsevering gelsolin/villin superfamily.  Its elevation might help to explain the 
increased actin levels observed in PDE.  
In contrast, 1antitrypsin and apolipoprotein AIV were both at noticeably lower levels in patients 
diagnosed with EPS.  1antitrypsin (1PI) is an inhibitor of ECM proteases including plasmin and 
suppresses the inflammatory response in PDE by inhibiting PAF biosynthesis.  Blocking of 1PI by 
oxidants during inflammatory process allows for increased production of PAF and unrestrained 
synthesis of inflammatory mediators(47).  Apolipoprotein AIV has antiinflammatory(48) properties. 
Therefore, lower levels of 1PI and apo AIV may indicate an active inflammatory process which might 
contribute to EPS development(49).  The latter is further supported by the observed increases in 
Complement factor expression(43).  Complement Factor I and factor B were consistently detected prior 
to (years before) and remained elevated in all patients who subsequently developed EPS.  Upon 
activation of the alternative pathway, Factor B is cleaved by complement factor D yielding the catalytic 
subunit Bb.  The active subunit Bb associates with C3b to form the alternative pathway C3
convertase, driving subsequent complement activation and inflammation.  Factor I (also known as 
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C3b/C4b inactivator) is a key regulator of downstream complement activity and its elevated levels are 
a further indicator of ongoing inflammatory activation in EPS patients. 
 Using iTRAQ analysis we demonstrated alterations in the effluent concentrations of acute 
phase proteins (APP).  Orosomucoid1 and a2HSglycoprotein chain B were both elevated in EPS 
patients >12 months prior to diagnosis whilst Apolipoprotein AIV was always low in EPS patients.  
Orosomucoid1 is a major APP.  Its concentration increases severalfold in response to inflammation, 
infection or systemic tissue injury(5051).  In PD patients, its dialysate levels increase during 
peritonitis(52).  Alpha2HeremansSchmid glycoprotein (AHSG), or fetuinA, has been suggested as a 
negative APP of inflammation(53) but as a positive APP of injury(54) and as an antagonist of TGF(55). 
The observed increase of these two molecules in the PDE, months before the onset of overt EPS, 
might underline a potential prognostic value.  Serotransferrin is the major iron transporter and is down
regulated in inflammatory conditions(5657). The observed late drop of serotransferrin levels might thus 
also reflect an increased inflammatory event that is critical in the establishment of fullblown EPS 
symptoms and pathology.  
 Complex biological samples are characterised by a high dynamic range of protein 
concentrations(58), posing a major challenge in proteomic analyses(59) as less abundant components 
are far more likely to be useful as biomarkers.  Combinatorial peptide ligand libraries (CPLL) can 
compress the dynamic range by altering the proportion of abundant versus nonabundant proteins(60). 
This approach was preferred over depletion protocols, where proteins of potential interest may also be 
removed nonspecifically by sticking to depleted proteins such as albumin.  Recovery of <1% of 
treated protein, increased the number and improved resolution of spots, indicating that proteome
mining was successful and increasing the sensitivity of 2D SDSPAGE.  Variability in spot intensities 
indicates that quantitative information was not lost during the mining process.  Comparisons between 
gels from CPLLmined samples identified that intelectin1, dermatopontin and retinol binding protein4 
appeared to be elevated in PD patients diagnosed with EPS compared to matched controls or those 
just starting on PD. Intelectin1 is an adipocytokine involved in intestinal host defences(61).
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Dermatopontin is an ECM protein that regulates the function of TGF by interacting with the 
proteoglycan decorin(62). Its presence in PDE might thus indicate increased turnover and accumulation 
of ECM in the peritoneum(63), being consistent with changes in Collagen 1 and HSPG.  
Overall the primary aim of this study was to identify early biomarkers for subsequent validation 
that would predict later risk of EPS.  This has been successful in identifying changes in Collagen 
a1(1), gActin, complement I & B as well as antitrypsin up to 3 to 5 years before EPS onset, with 
Gelsolin, Apo AII, ApoAIV & haemoglobin b changing at least 2 years before onset, although caution 
should be exercised with these time frames due to the large variation in time on PD between the 
matched populations.  The study also identified late markers such as serotransferrin, Orosomucoid1, 
Alpha2HSglycoprotein chain B and intellectin1 which may have diagnostic value when combined 
with symptoms.  One could further hypothesise that this data supports the multiple hit theory of EPS 
with early, mid and late protein changes in that there may be a timepoint where a second hit drives 
the process into the EPS pathway post an initial hit priming the system (eg. reflected by changes in 
Collagen I and Actin). From that time on, the inflammatory and other processes that lead to the 
development of EPS may need 612 months to fully develop into a recognisable clinical syndrome.  Its 
thus likely, and reflected here, that biomarkers would fall into the same 2 categories.  
While of interest, the robustness of our findings is significantly limited by the low number of 
patients available for suitable stratification and the limited numbers that can be compared in these 
proteomic approaches.  The GFS is one of the worlds largest PD cohort studies, yet has limited EPS
tocontrol matching options, resulting in some differences in descriptive data to remain apparent.  As 
with all previous studies in this area, it is possible that differences in measured and unmeasured 
confounders could be biasing the results.  Further, the selected proteomics approach was not able to 
determine the source of the proteins identified in this analysis and a possible spillover effect from 
plasma cannot be excluded which needs to be addressed in ongoing investigations. 
Previous studies have suggested that a number of proteins, primarily inflammatory biomarkers 
(IL6, TNF, MCP1, CCL15, PAI1), were slightly increased in the PDE of patients who 
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subsequently developed EPS(10,49,6465), but were not identified by our proteomics approach.  Previous 
studies used a targeted ELISA based approach, which has high sensitivity and subsequently 
resolution.  Proteins identifiable with ELISA may subsequently fall below the detection limit of the 
proteomics approaches described, especially where proteinmining was not undertaken.  Further, the 
proteomic technique may be unable to see the protein in the matrix used.  Protein spots may not 
resolve, while highmatching criteria (4 peptides minimum) may have disadvantaged detection of 
smaller proteins.  Alternatively, proteins may have not flown in the MS or not label with an isobariq tag. 
Finally, the small number of patients, the frequency of the change (i.e. spot changes in >75% of 
comparisons) or its magnitude could impede identification.  Multiplexing approaches are more 
sensitive and quantitative, and could have been used here.  However the investigator must select the 
list of proteins to measure, which precludes discovery of new protein involvement.  Further these 
approaches demand high sample number and would not add power to the results described due to the 
very small number of EPS samples in the GFS cohort.  
In contrast, the strengths of this study lie in its prospective nature, its unbiased nature and 
multiple proteomic approaches.  Prospective analysis has resulted in identifying changes that occur 
consistently over time (and prior to disease onset in many cases), are robust across multiple 
comparisons and differentiate between EPS and control patients.  The discoverybased approach, has 
allowed the analysis to be undertaken without prejudice for already known proteins and pathways, 
thus reducing protein selection bias and potentially allowing the discovery of novel markers of 
peritoneal fibrosis and EPS.  
Collectively, the study results demonstrate that progressive and consistent changes in th e 
PDE proteome can be identified in PDE samples derived from patients who subsequently developed 
EPS. The majority of the proteins identified in EPS patients are consistent with their potential 
involvement in inflammation, the acute phase response, fibrogenenesis and ECM turnover (Table 2).  
This novel data supports the need for further investigation using classical measurement techniques.  
Future studies should focus on the quantitative investigation of the proteins identified here and in other 
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studies, in large, multicenter, wellstratified PD patient cohorts to provide robust validation of the use of 
these proteins as potential predictive and diagnostic tools, either individually or as part of a fingerprint. 
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Methods  
(Comprehensive description of methods used provided in supplementary material) 
Patient Cohorts, Matching and Sample Collection 
Patients were drawn from the Global Fluid Study (GFS)(66) and a smaller singlecentre cohort from the 
University of Patras, Greece. The GFS cohort provided prospectively collected effluent samples from 
patients with confirmed diagnosis of EPS and control patients primarily matched for treatment 
exposure (time on PD or time to EPS/stopping PD) and centre (Supplemental tables 1&2).  The Greek 
cohort provided single, large volume samples from nine selected patients, needed for the optimization 
of Proteominer for use with PDE.  The study was conducted adhering to the tenets of the 
Declaration of Helsinki and informed consent was obtained from all patients.  Ethical approval was 
obtained from the MultiCentre Research Ethics Committee for Wales covering the UK, whilst local 
country ethics were obtained for other contributing countries. The clinical and demographic 
characteristics of participating patients from both cohorts are summarised in Table 3a and 3b, 
respectively.  
Sample preparation 
 Total protein was precipitated using acetone/100%TCA, and resolubilised in buffer. 60g of 
protein were loaded on pH 47 immobilised pH gradient (IPG) strips (BioRad Laboratories Ltd., 
Hercules, CA, U.S.A.). 
Twodimensional electrophoresis
 Isoelectric focusing (IEF) was performed in a PROTEAN IEF system using a fourstep protocol 
and subsequently, proteins were fractionated on a 20 x 23cm 10% polyacrylamide gel using a 
PROTEAN Plus Dodeca Cell system (BioRad Laboratories Ltd., Hercules, CA, U.S.A.). 
Gel fixing and silver staining 
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 Gels were fixed using 40% methanol and 10% acetic acid and silverstained as described 
elsewhere.(67)
Gel Imaging
 Gels were scanned on a Genetools densitometer (transmission) and PDQuest v8.0 (BioRad 
Laboratories Ltd., Hercules, CA, U.S.A.) was used for image analysis.  
Proteome mining
 Proteominer (Biorad, Laboratories Ltd., Hercules, CA, U.S.A.) was employed, using a 20l of 
beads to 10 mg of protein ratio and a twostep elution protocol.(68)
iTRAQ labeling 
 Sample labeling with iTRAQ reagents was performed as described elsewhere.(69) Briefly, 
100µg of protein from each sample was reduced, alkylated and digested with trypsin, prior to labeling 
(iTRAQ® Reagents  8plex, AB SciexTM, Framingham, MA, USA).  
Strong Cation Exchange (SCX) Fractionation of Peptides   
Briefly, SCX was carried out using a PolySULFOETHYL A Column (PolyLC, Columbia, MD) 
5µm particle size of 200mm length×2.1mm id, 200Å pore size, on a BioLC HPLC unit (Dionex, 
Surrey, UK). The chromatogram was monitored through a UV Detector (Dionex/LC Packings, 
Amsterdam, the Netherlands), at 214nm. 
Mass Spectrometry (MS) 
 Mass spectrometry was performed using a QStar XL Hybrid ESI Quadrupole timeofflight 
tandem mass spectrometer, ESIqQTOFMS/MS (Applied Biosystems; MDSSciex) coupled to an 
online capillary liquid chromatography system (U3000, Thermo, Hemel Hempstead, UK). Peptides 
were separated on a PepMap C18 RP capillary column (LC Packings).
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MS Data Analysis 
 Peak list conversion was performed using the mascot.dll embedded script (V1.6) coupled with 
Analyst QS 1.1.1 (ABSCIEX, Framingham, MA, USA). Protein identification and relative quantification 
was carried out in Phenyx v2.6 (GeneBio S.A., Geneva, Switzerland), using a human protein 
database. False discovery rate (FDR) was calculated using a decoy database automatically created 
by reversing the sequences from the target database(70) and was found to be 1%. Figures show 
exemplar data and samples for iTRAQ were pooled and thus do not include standard errors. For 
Figure 7, multiple samples from 2Dgels run concurrently have been combined to provide a mean and 
therefore the standard errors were calculated..
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Legends: 
Figure 1: Exemplar images showing the changes in the PD fluid proteome over 4 years on 
dialysis in a patient with stable membrane function using 2D PAGE  
10 PDE samples spanning days 9 to 1410 of peritoneal dialysis of approximately 2 ml volume were 
precipitated with 3.5 volume of acetone/10% TCA and the pellet was resolubilised in buffer.  A volume 
equivalent to 60g of protein was subjected to isoelectric focusing on a pH 47 IPG strip (BioRad) 
using passive rehydration with proteins further separated on a BioRad Dodeca gel system and 
fractionated overnight.  Each gel was recovered and silver stained using the Blum method. Gels were 
scanned on a Genetools densitometer (transmission), entered into PDQuest software and spot 
patterns compared.  Exemplar images from GFS patient G01029 (stable membrane function). 
Figure 2: Fibrinogen chain (a) and Heparan sulphate proteoglycan (b) are elevated in PD fluid 
with time on PD in a patient with stable membrane function (exemplar images). 
Exemplar images from patient G05068 (stable membrane function). 10 PD fluid samples were 
available, ranging from day 30 through to day 3013 on PD that were analysed for spot changes as in 
figure 1. Protein spots 6001 (a) and 6003 (b) were identified as changing with time on PD by 
PDQUEST software based on spot volume density. These were excised from the gel and subjected to 
MALDITOF Mass spectrometry. The proteins were identified as fibrinogen chain (a) and heparan 
sulphate proteoglycan (HSPG) (b).  Graphs show a single spot volume density at all 10 timepoints 
from 1 x 10 gel run.  Fibrinogen g chain gel images depict changes occurring beween 2 ½ & 5 years 
where as HSPG shows images up to 3 years. 
Figure 3: Collagen a(1)I (a) and actin (b) are elevated in a patient with EPS 5 years before EPS 
diagnosis (exemplar images) 
Exemplar images from GFS patients G05072 (confirmed EPS) and G05068 (stable membrane 
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function).  5 PD fluid samples were available from patient G05072, spanning days 1043 to 2868 of 
PD.  These were matched to 5 samples from patient G05068, based on time from start of PD and 
comparative 2D SDSPAGE proteomics undertaken as in figure 1.  Two spots as identified with a black 
arrow in both panels were seen to be consistently elevated in all EPS patients at all time points which 
was confirmed by volume densitometric analysis.  This protein spots were excised from the gel and 
subjected to MALDITOF mass spectrometry.  The proteins were identified as a fragment of collagen 
1(I) (a) and as actin (b).  Of note, the spot identified by a white arrow in panel (a) at 55kDa was 
only elevated in this single EPS patient.  Graphs show a single spot volume density at all 5 time points 
from 1 x 10 gel run with the first 5 bars being the identified spot in the EPS sample and the second 5 
bars the stable patient plotted in chronological area. 
Figure 4: Complement factors I and B increase in EPS 5 years before diagnosis (exemplar 
images). 
Exemplar images from GFS patients G05072 (confirmed EPS) and G05068 (stable membrane 
function).  5 PD fluid samples were available from patient G05072, spanning days 1043 to 2868 of 
PD.  These were matched to 5 samples from patient G05068 based on time from start of PD and 
comparative 2D SDSPAGE proteomics performed as figure 1.  Two spots that were elevated by 
volume densitometry in EPS in this and 3 out of 4 other patient comparison runs were identified as 
complement factor I (black arrow) and complement factor B (white arrow). 
Figure 5: iTRAQ identifies 4 proteins with altered levels in an EPS patient compared to a 
matched control. 
 Four PD samples from patient G05072 (confirmed EPS) were matched with 4 PD samples from 
patient G05068 (stable membrane function), by time to finishing dialysis.  Each sample was 
precipitated in 3 volumes of acetone/10% TCA, redissolved & then buffer exchanged into 
triethylammonium bicarbonate (TEAB).  50 g of protein was denatured in tris(2
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carboxyethyl)phosphine and reduced in methylmethanethiosulfonate prior to trypsin digestion.  Each 
sample was then labelled with a different isobariq tag using the 8 label iTRAQ system.  All samples 
were mixed, fractionated by RPHPLC and proteins identified by MODITOF MS.  For each of 72 
proteins detected, the ratio of each protein was calculated based on the abundance of each isobariq 
tag within that protein sample.  Using this approach 4 proteins showed consistent trends.  
Orosomucoid1 and 2HSglycoprotein chain B were both elevated in the EPS patient some 12 
months before diagnosis, while Apolipoprotein AIV was always low in EPS with a dramatic late drop in 
serotransferrin.  Data shown represents fold change in the confirmed EPS patient compared to the 
patient with stable membrane function and is from a single experimental run. 
Figure 6: ProteoMiner allows detection of lower abundance proteins in PD fluid 
A PD fluid volume equivalent to 15mg of protein was reduced to 500l volume using a 3kDa molecular 
weight cut off concentrator.  10mg of protein was then subjected to the low abundance protein 
enrichment using the BioRad ProteoMiner system using 20l of beads.  100 g of eluted protein 
and that from the original PD fluid samples was precipitated using 3 volume acetone/10% TCA and 
comparative analysis performed using 2D SDS PAGE proteomic analysis as in figure 1.  The total 
number of resolved protein spots was calculated using PDQUEST. 
Figure 7: In protein mined PD fluid Intelectin1  (a) and dermatopontin (b) are elevated in EPS.
From a Greek cohort of PD fluid samples (University of Patras), fluid was taken from 3 patients with 
suspected EPS (2 of them confirmed postportem), 3 patients who had remained on PD for more than 
5 years but had no signs of EPS (late controls) and 3 patients with samples taken within the first 
month of starting PD (early controls).  A volume equivalent to 15mg of protein was concentrated and 
subjected to ProteoMiner enrichment as in figure 6.  Samples were then subjected to 2D SDS
PAGE analysis as in figure 1, with spots identified as different between the EPS (column 1), late 
controls (column 2) and early controls (column 3) identified using PDQUEST.  Spot 7203 (a) was 
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identified as being elevated in all 3 patients with EPS, which was confirmed by subsequent volume 
densitometry measurement of the spot in all 9 samples.  Spot 1001 (b) was identified as being 
elevated in all 3 patients with EPS and one of the late controls, which was confirmed by subsequent 
volume densitometry measurement of the spot in all 9 samples.  These spots were subsequently 
excised from the gel and identified by MALDITOF as intelectin1 (a) and Dermatopontin (b).  Spot 
volume densitometry from all 3 patients in each group was averaged with data presented as 
mean±SEM in the 2 bar graphs.  Significance was determined by 1 way ANOVA, * p<0.05, ** p<0.01 
compared to early PD control group. 
Figure 8: Analysis of pooled samples at four matched timepoints using iTRAQ after treatment 
with Proteominer. 
Patient samples were pooled into 4 groups based on time (>24 mths, 1224 mths, 612 mths , <6 
mths) to developing EPS or stopping PD.  Each pool consisted of equal amounts of protein from each 
sample available. Post pooling they were processed using ProteoMiner, iTRAQ labelled, 
fractionated by RP HPLC and then subjected to tandem MS.   
Figure 9: Hierarchical Cluster analysis (a) and heatmap (b) of proteins detected from proteome
mined pooled EPS PD effluent iTRAQ analysis. 
The relative contribution of each pooled cohort to the total level of each protein identified was made 
based on the abundance of each isobariq tag.  The proteins detected in each cohort were then used to 
position each as a hierarchical cluster. E=EPS, N=Normal (stable PD), E1/N1 = >24 mths, E2/N2 = 12
24, E3/N3 = 612 mths and E4/N4= <6Mths to EPS or stopping PD (a). The variation in each protein 
detected in each cohort was then plotted as a heat map (b). Arrows indicate Intellectin1 and Gelsolin. 
Data is from a single run. 
Figure 10: Relative changes in proteins showing progressive variation with time in pooled 
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cohorts of EPS patients subjected to protein mining and ITRAQ analysis. 
Relative levels of intelectin1, Gelsolin, Apolipoprotein AII and Heamaglobin beta subunit were 
determined by calculating the ratio to the >24month cohort level in the patients not developing EPS.  
Data represents ratio to >24month stable patient from a single run of pooled samples. 
Table 1: Proteins detectable by iTRAQ in PD fluid 
Total proteins identified in PD fluid samples by iTRAQ.  Identification is based on at least 3 different 
identifiable sequences within a protein. 
Table 2: Top potential hits for EPS bio markers from 2D PAGE & iTRAQ proteomics  
From all 2D SDSPAGE proteomics using mined and unmined samples plus iTRAQ studies, proteins 
that were significantly altered in at least 75% of patients with EPS and less than 10% of nonEPS 
patients were shortlisted as those most likely to have value as prognostic or diagnostic markers of 
EPS.  For 2D gels data shows number of patients showing the change out of total evaluated.   
Table 3: Patient Demographics for (a) the GFS and (b) the University of Patras cohorts. 
Figures are given as mean (SD), median (range) and percentages as appropriate.  For iTRAQ 
analysis of protein mined samples (a), GFS effluent samples were pooled into 4 groups based on time 
to developing EPS or stopping PD: Group 1; < 6 months prior to EPS or stopping dialysis, Group 2; 6
12 months prior to stopping dialysis, Group 3; 12 to 24 months prior to stopping dialysis and Group 4; 
greater than 24 months before cessation of dialysis (see also figure 8).  Each group consisted of 5 to 7 
patient samples. 
Comorbidity was documented using the validated Stoke Comorbidity Index, which both categorizes 
patients into lowrisk (score 0), intermediaterisk (score 12), and highrisk (score >2) groups and 
enables analysis by individual comorbid conditions within the index(39). 
For the ProteoMiner experiments, a single peritoneal fluid sample was obtained from each of nine 
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selected patients from a cohort of Greek PD patients (b). 
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Patients and Methods 
Patient Cohorts, Matching and Sample Collection
 Patients were drawn from two cohorts, the Global Fluid Study (GFS), an 
international, multicentre, prospective, observational cohort study seeking to relate 
peritoneal membrane function to local and systemic biomarkers as predictors of 
predefined clinical endpoints (e.g. patient survival, membrane injury)(66), and a 
smaller singlecentre cohort of Greek patients. GFS recruited incident (within first 90 
days of PD) and prevalent patients from 10 participating centres from the UK, Korea 
and Canada between June 2002 and December 2008.  Dialysate sampling was from 
a 4hour peritoneal equilibration test (PET) using a 2.27% glucose bag, with 
simultaneous clinical data collected and stored in a purpose built Peritoneal Dialysis 
Access database (PDDB). The study was conducted adhering to the tenets of the 
Declaration of Helsinki and informed consent was obtained from all patients.  Ethical 
approval was obtained from the MultiCentre Research Ethics Committee for Wales 
covering the UK, whilst local country ethics were obtained for other contributing 
countries.  
For this analysis, EPS patients were identified according to ISPD guidelines(1) in 5 UK 
centres.  For 2D gel proteomics, Global patients were matched primarily on the  
duration of PD and centre, which in some comparisons required 2 control patients.  
Closer matching was not possible due to the limited number of patients having 
prolonged exposure to PD.  For ITRAQ proteomics, Global patients were matched 
based on time to EPS.  For pooled studies, 10 EPS patients and 18 with stable 
membrane function were divided into 4 time segmentsof <6 months, 6 to 12 months, 
12 to 24 months and >24 months from EPS or stopping PD (supplemental table 1).  
Each pool consisted of between 5 and 7 samples which together made up a 
minimum amount of 18.8mg of starting protein.  This protein pool was made up using 
equivalent protein amounts from all patients contributing to the pool.  The 
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demographic and clinical characteristics of these patients and their controls, including 
the number of samples analysed and their temporal matching is summarized in Table 
3a. 
 To optimise ProteoMiner for use with PDE, experiments requiring larger 
dialysate volumes, samples from a smaller PD effluent repository based at the 
University Hospital of Patras, Greece were used.  This repository was created in 
2009 with the aim to collect samples of peritoneal tissue and PDE, to study potential 
correlations between effluent markers of inflammation and fibrosis and biopsy 
findings at catheter placement and removal.  The project, was approved by the Ethics 
Committee of the University Hospital of Patras and informed consent was obtained 
from incident (scheduled for peritoneal catheter placement) and prevalent patients 
receiving PD treatment in the same centre.  100ml PDE samples from overnight (8
hour) dwells (Physioneal® 40 Glucose 1.36% w/v, Baxter Healthcare Ltd.) were 
collected at recruitment (within the first month from PD start for incident patients) and 
at 6month intervals thereafter.  Samples were also obtained at PD stop, due to 
kidney transplant or transfer to hemodialysis.  At each sampling visit, clinical and 
demographic data were collected and stored in a database.  For the present analysis 
a single sample from each of nine selected patients was analysed.  Selected patients 
included three incident patients, three prevalent patients with >5 years on PD and 
stable membrane function and three prevalent patients with suspected EPS based on 
clinical presentation.  In two of the latter, EPS diagnosis was confirmed at autopsy.  
The third patient was lost to follow up after having been transferred to hemodialysis 
at another institution.  The demographic and clinical characteristics of these patients 
are summarized in Table 3b. 
Sample preparation 
 All samples were stored in 80o C and thawed for aliquoting and just prior to 
use in experiments.  Total protein was precipitated using 3.5 volumes of acetone 
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chilled at 20oC and 0.5 volumes of 100%TCA for every volume of sample. 
Subsequently, samples were centrifuged in a Sigma 318 centrifuge (Sigma 
Laborzentrifugen GmbH, Germany) at 4248 RCF for 40 minutes, at a temperature of 
10oC.  The protein pellet was resolubilised in 500l of buffer containing 8M urea, 2M 
thiourea, 4% CHAPS, 0.2% (v/v) ampholytes (pH 4-7, 100 mM DTT, 40 mM 
Tris-base, and 0.0002% bromophenol blue in 18.2MOhm water.  To facilitate re
solubilisation, samples were vortexed for 30 seconds and sonicated in a cold water 
bath for 15 minutes.  Following resolubilisation, protein concentration was 
determined using the Thermo Scientific Pierce 660nm Protein Assay (Thermo Fisher 
Scientific Rockford, IL., U.S.A), according to manufacturers instructions.  A volume 
corresponding to 60g of protein was increased to a final volume of 350l by adding 
solubilisation buffer.  This volume was loaded on a pH 47 immobilised pH gradient 
(IPG) strip (BioRad Laboratories Ltd., Hercules, CA, U.S.A.), covered with 3ml of 
mineral oil and left overnight to allow complete absorption on the strip. 
Isoelectric Focusing
 Loaded IPG strips were subjected to isoelectric focusing (IEF) using a 
PROTEAN IEF system (BioRad Laboratories Ltd., Hercules, CA, U.S.A.).  Default 
temperature was set to 20oC.  A fourstep programme was used as follows: Step 1: 
250V over 4.5 hours. Step 2: linear increase up to 10,000V over 2.5 hours. Step 3: 
instant increase up to 10,000V until 50,000 V*h were completed.  Step 4: instant 
decrease down to 500V until 70,000 V*h were completed.    
SDS-PAGE
 Following isoelectric focusing, IPG strips were bathed in 2% DTT followed by 
2.5% iodoacetamide in equilibration buffer for 15 minutes.  Equilibration buffer 
contained 36% (w/v) urea, 20% glycerol, 2% SDS and 0.005M TrisHCl (pH 8.8).  
Proteins were subsequently fractionated on a 20 x 23cm 10% polyacrylamide gel 
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containing 0.1% SDS, 2.5% Rhinohide™ (Invitrogen), 0.05% APS, 0.025% TEMED 
and 0.375M TrisHCl.  After casting the gels in the casting chamber, 1ml of 50:50 
water saturated butan2ol was added on top of each gel to remove air bubbles and 
create a flat surface where the IPG could be applied. 1% overlay agarose (with 
Bromophenol Blue to observe dye front) secured the IPG.  Gels were allowed to set 
for 2 hours, then washed 3 times with ultrapure water and finally washed with 
running buffer (25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3) and stored at 4oC 
until use. For SDSPAGE a PROTEAN Plus Dodeca Cell system was used (BioRad 
Laboratories Ltd., Hercules, CA, U.S.A.).  Voltage was set to 80V for a minimum of 4 
hours and then turned down to 40V until electrophoresis was complete.  
Gel fixing and silver staining 
 After electrophoresis, each gel bathed in fixing solution containing 40% 
methanol and 10% acetic acid in deionized water for 2 hours.  Subsequently gels 
were washed with 30% ethanol in water, 3 times for 20 minutes each.  For silver 
staining, an optimised protocol based on the method described by Blum et al. was 
used(67)  First gels bathed in 0.035% sodium thiosulfate for 90 seconds and then 
were washed with deionized water 3 times, 20 seconds each.  Subsequently, 0.2% 
silver nitrate, 0.02% formaldehyde solution was added for 20 minutes and then gels 
were washed again 3 times with deionized water, for 20 seconds each.  Silver 
solution was followed by the developer solution containing 3% sodium carbonate, 
0.003% sodium thiosulfate pentahydrate and 0.05% formaldehyde.  The developer 
solution was decanted after 5 minutes, provided that visualization of protein spots 
was clear.  Two 30 second washes with water followed before the stop solution 
containing 0.5% glycine was added for 10 minutes.  Finally, the stop solution was 
decanted and gels were washed with water twice, for 30 minutes each time.   
Gel Imaging
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5
 Gels were scanned on a Genetools densitometer (transmission).  PD Quest 
v8.0 (BioRad Laboratories Ltd., Hercules, CA, U.S.A.) was used for analysis of the 
gel images.  
Proteome mining
 This was undertaken using the Proteominer small capacity kit (Biorad, 
Laboratories Ltd., Hercules, CA, U.S.A.).  A volume of sample corresponding to 
15mg of protein was centrifuged using a 3kDa cutoff filter until reduced to 500l. 
Subsequently, volumes corresponding to 10mg of protein were mined as per 
manufacturers instructions using a ratio of 20l of beads to 10 mg of protein.  Elution 
with 8M urea/2% CHAPS rehydrated with 5% acetic acid, was followed by a second 
elution using 4% boiling SDS, 25mM DTT to increase recovery(68)   Finally, protein 
concentration was determined prior to isoelectric focusing or iTRAQ. 
iTRAQ  
 iTRAQ provides a method for simultaneous protein identification and relative 
quantification in multiplex format. It is a widely used quantitative proteomic strategy in 
clinical proteomic research, including for biomarker discovery. During 
iTRAQ  analysis, peptides from each sample (post proteolytic digestion preparation 
step) are labeled with one of the set of reagents, then combined. The iTRAQ 
reagents are isobaric and thus a labeled peptide set (for a specific amino acid 
sequence) will have the same mass in all samples at this stage. Peptide identity and 
the samples in which it is found is determined by tandem mass spectrometry, which 
selects a specific set of peptides for fragmentation to yield sequence ions and ions 
for relative quantification.  This data provides information on the relative abundance 
of a particular peptide across all samples within the experiment.  Quantification data 
is based on unique low mass 'reporter ion' (to each iTRAQ label).  Reporter ion 
intensity information is used to calculate fold change relative to a designated control.  
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We used an in house statistical analysis pipeline, as detailed in Pham et al. 2010(69)
to i) integrate all the peptide measurement data to the protein level and ii) to 
determine proteins altered in level between samples (p value <0.05). Sample labeling 
with iTRAQ reagents was performed as described elsewhere(70) and as 
recommended by the manufacturer.  One hundred micrograms of protein from each 
sample (or pool) was reduced, alkylated then digested with trypsin, prior to labeling 
(iTRAQ® Reagents  8plex, AB SciexTM, Framingham, MA, USA). 
Strong Cation Exchange (SCX) Fractionation of Peptides  
 The fractionation was performed as described elsewhere(41). Briefly, SCX was 
carried out using a PolySULFOETHYL A Column (PolyLC, Columbia, MD) 5µm 
particle size of 200mm length×2.1mm id, 200Å pore size, on a BioLC HPLC unit 
(Dionex, Surrey, UK).  The 60min gradient was generated between Buffer A (10mM 
KH2PO4 and 25% acetonitrile, pH 3.0), and Buffer B (10mM KH2PO4, 25% 
acetonitrile and 500mM KCl, pH 3.0), and consisted of 100% A for 5min, 530% B 
for 40min, 30100% B for 5min, 100% B for 5min and finally 100% A for 5min.  The 
chromatogram was monitored through a UV Detector (Dionex/LC Packings, 
Amsterdam, the Netherlands), at 214nm.  Individual SCX fractions were pooled for 
subsequent nanoLCMS/MS analysis.  Pooled fractions were dried in a vacuum 
concentrator (Eppendorf, Hamburg, Germany), and stored at -20°C prior to analysis 
by mass spectrometry.
Mass Spectrometry (MS) 
Page 37 of 62
The International Society of Nephrology (http://www.isn-online.org/site/cms)
Kidney International
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
7
Each peptide fraction was redissolved in 20µl of 0.1% formic acid and 3% 
acetonitrile and then 6µl of sample was injected into the nanoLCESIMS/MS 
system for analysis.  Mass spectrometry was performed using a QStar XL Hybrid 
ESI Quadrupole timeofflight tandem mass spectrometer, ESIqQTOFMS/MS 
(Applied Biosystems; MDSSciex) coupled to an online capillary liquid 
chromatography system (U3000, Thermo, Hemel Hempstead, UK).  Peptides were 
separated on a PepMap C18 RP capillary column (LC Packings), with a constant 
flow rate of 0.3µl/min.  The LC gradient started with 3% Buffer B (0.1% formic acid in 
97% acetonitrile) and 97% Buffer A (0.1% formic acid in 3% acetonitrile) for 3min, 
followed by 330% Buffer B for 90min, then 90% Buffer B for 7min, and finally 3% 
Buffer B for 8min.  The mass spectrometer was set to perform data acquisition in the 
positive ion mode, with a selected mass range of 4001,600m/z.  Peptides with +2 to 
+4 charge states were selected for tandem mass spectrometry, and the time of 
summation of MS/MS events was set to 3sec.  The two most abundantly charged 
peptides above a threshold of five counts were selected for MS/MS, and dynamically 
excluded for 60sec with a ±50mmu mass tolerance.
MS Data Analysis
 Peak list conversion was performed using the mascot.dll embedded script 
(V1.6) coupled with Analyst QS 1.1.1 (ABSCIEX, Framingham, MA, USA) with 
MS/MS group summations and the iTRAQ region deisotoping removed.  Protein 
identification and relative quantification was carried out in Phenyx v2.6 (GeneBio 
S.A., Geneva, Switzerland), using a human protein database.  General search 
parameters allowed for MS and MS/MS tolerance up to 0.1 Da and one missed 
cleavage.  Fixed protein modifications included iTRAQ lysine and iTRAQ Nterminus 
(+304 Da) and methylthiol of cysteines (+46 Da), variable modifications were 
oxidation of methionine (+16 Da).  The acceptance parameters for peptide 
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identification were peptide length ³6, zscore ³5.0 and pvalue £1.0 e4.  False 
discovery rate (FDR) was calculated using a decoy database automatically created 
by reversing the sequences from the target database(71) and was found to be 1%. 
Bias normalization for whole proteome analyses were also performed by correcting 
the bias median ratio of each comparison toward unity. Figures show exemplar data 
and samples for iTRAQ were pooled and thus do not include standard errors.  For 
Figure 7, multiple samples from 2Dgels have been combined to provide a mean and 
therefore the standard error was calculated.
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Supplemental Table 1: Patient sample matching for 2D gel comparisons
Patient Code
EPS vs Stable PD 
Days from starting PD
Point 1 Point 2 Point 3 Point 4 Point 5
G05-072 vs. 
G05-068 
1043 vs 1089 1448 vs 1490 2429 vs 2430 2538 vs 2564 2868 vs 2013 
G05-134 vs 
G01-029 
9 vs 9 181 vs 203 376 vs 203 933 vs 870 - 
G03-016 vs
G03-022 
772 vs 828 870 vs 869 1141 vs 1136 1297 vs 1213 - 
G01 001 vs 
G01 030 
1204 vs 1142 1567 vs 1497 2177 vs 2241 2350 vs 2439 - 
G01-001 vs 
G01-15 
774 vs 785 960 vs 953 1142 vs 1165 1346 vs 1347 - 
G05-018 vs 
G03-006 
34 vs 90 258 vs 294 435 vs 447 664 vs 665 - 
G05-72 vs 
G0157 
2009 vs 2170 2429 vs 2382 2638 vs 2501 2868  vs 2737 - 
EPS and stable PD patient samples were matched at up to 5 time points from the date of starting PD 
for 2D Gel proteomic analysis.  Each comparison shows the day that the sample was collected from 
the EPS patient versus the day from the stable PD patient 
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Supplemental table 2: Breakdown of EPS and control sample pooling for 
iTRAQ analysis on protein mined PDE 
EPS samples were pooled by time to developing EPS or stopping PD with stable function into cohorts 
of <6 months, 6-12 months, 12-24 months and .24 months.  Each pool contained samples that 
together gave a minimum of 18.8 mg of protein.  All patients (5 to 7) in a pool contributed an equal 
amount of protein.  Some patients contributed to all pools, and some just 1.  Y denotes inclusion in 
the pool. GXX denotes the centre and the following number the patient at that centre.   
Patient Code Condition <6 months 6-12 Mths 12-24 Mths >24 Months Number 
of Time 
points 
G05-072 EPS Y Y Y Y 4
G05-134 EPS Y Y 2
G03-016 EPS Y Y Y 3
G05-092 EPS Y 1
G05-010 EPS Y Y 2
G01-008 EPS Y Y Y 3
G05-029 EPS Y 1
G05-018 EPS Y Y 2
G01-001 EPS Y 1
G02-052 EPS Y 1
EPS pooled @ 
each time point 
 5 5 5 5 
G05-042 Stable PD Y 1
G05-002 Stable PD Y 1
G03-006 Stable PD Y 1
G05-093 Stable PD Y Y 2
G03-021 Stable PD Y Y 2
G05-050 Stable PD Y 1
G05-090 Stable PD Y 1
G05-123 Stable PD Y 1
G01-011 Stable PD Y Y Y 3
G05-077 Stable PD Y 1
G05-119 Stable PD Y 1
G05-026 Stable PD Y 1
G03-018 Stable PD Y Y 2
G05-085 Stable PD Y 1
G05-041 Stable PD Y 1
G01-031 Stable PD Y 1
G05-069 Stable PD Y 1
G01-069 Stable PD Y 1
G02-066 Stable PD Y 1
Stable pooled @ 
each time point
6 5 6 7 
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Figure 1: Exemplar images showing the changes in the PD fluid proteome over 4 years on dialysis in a 
patient with stable membrane function using 2D PAGE  
10 PDE samples spanning days 9 to 1410 of peritoneal dialysis of approximately 2 ml volume were 
precipitated with 3.5 volume of acetone/10% TCA and the pellet was re-solubilised in buffer.  A volume 
equivalent to 60µg of protein was subjected to isoelectric focusing on a pH 4-7 IPG strip (Bio-Rad) using 
passive rehydration with proteins further separated on a Bio-Rad Dodeca gel system and fractionated 
overnight.  Each gel was recovered and silver stained using the Blum method. Gels were scanned on a 
Genetools densitometer (transmission), entered into PDQuest software and spot patterns 
compared.  Exemplar images from GFS patient G01-029 (stable membrane function).  
Figure 1  
1270x952mm (120 x 120 DPI)  
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Figure 2: Fibrinogen chain (a) and Heparan sulphate proteoglycan (b) are elevated in PD fluid with time on 
PD in a patient with stable membrane function (exemplar images).  
Exemplar images from patient G05068 (stable membrane function). 10 PD fluid samples were available, 
ranging from day 30 through to day 3013 on PD that were analysed for spot changes as in figure 1. Protein 
spots 6001 (a) and 6003 (b) were identified as changing with time on PD by PDQUEST software based on 
spot volume density. These were excised from the gel and subjected to MALDITOF Mass spectrometry. The 
proteins were identified as fibrinogen chain (a) and heparan sulphate proteoglycan (HSPG) (b).  Graphs 
show a single spot volume density at all 10 timepoints from 1 x 10 gel run.  Fibrinogen  chain gel images 
depict changes occurring beween 2 ½ & 5 years where as HSPG shows images up to 3 years.  
Figure 2a  
1270x952mm (120 x 120 DPI)  
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Figure 2: Fibrinogen chain (a) and Heparan sulphate proteoglycan (b) are elevated in PD fluid with time on 
PD in a patient with stable membrane function (exemplar images).  
Exemplar images from patient G05068 (stable membrane function). 10 PD fluid samples were available, 
ranging from day 30 through to day 3013 on PD that were analysed for spot changes as in figure 1. Protein 
spots 6001 (a) and 6003 (b) were identified as changing with time on PD by PDQUEST software based on 
spot volume density. These were excised from the gel and subjected to MALDITOF Mass spectrometry. The 
proteins were identified as fibrinogen chain (a) and heparan sulphate proteoglycan (HSPG) (b).  Graphs 
show a single spot volume density at all 10 timepoints from 1 x 10 gel run.  Fibrinogen  chain gel images 
depict changes occurring beween 2 ½ & 5 years where as HSPG shows images up to 3 years.  
Figure 2b  
1270x952mm (120 x 120 DPI)  
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Figure 3: Collagen a(1)I (a) and actin (b) are elevated in a patient with EPS 5 years before EPS diagnosis 
(exemplar images)  
Exemplar images from GFS patients G05072 (confirmed EPS) and G05068 (stable membrane function).  5 
PD fluid samples were available from patient G05072, spanning days 1043 to 2868 of PD.  These were 
matched to 5 samples from patient G05068, based on time from start of PD and comparative 2D SDSPAGE 
proteomics undertaken as in figure 1.  Two spots as identified with a black arrow in both panels were seen 
to be consistently elevated in all EPS patients at all time points which was confirmed by volume 
densitometric analysis.  This protein spots were excised from the gel and subjected to MALDITOF mass 
spectrometry.  The proteins were identified as a fragment of collagen 1(I) (a) and as actin (b).  Of note, 
the spot identified by a white arrow in panel (a) at 55kDa was only elevated in this single EPS 
patient.  Graphs show a single spot volume density at all 5 time points from 1 x 10 gel run with the first 5 
bars being the identified spot in the EPS sample and the second 5 bars the stable patient plotted in 
chronological area.  
Figure 3a, Figure 3b  
1270x952mm (120 x 120 DPI)  
Page 45 of 62
The International Society of Nephrology (http://www.isn-online.org/site/cms)
Kidney International
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
Figure 4: Complement factors I and B increase in a patient with EPS 5 years before diagnosis (exemplar 
 images). Exemplar images from GFS patients G05-072 (confirmed EPS) and G05-068 (stable membrane 
function).  5 PD fluid samples were available from patient G05-072, spanning days 1043 to 2868 of 
PD.  These were matched to 5 samples from patient G05-068 based on time from start of PD and 
comparative 2D SDS-PAGE proteomics performed as figure 1.  Two spots that were elevated by volume 
densitometry in EPS in this and 3 out of 4 other patient comparison runs were identified as complement 
 factor I (black arrow) and complement factor B (white arrow).   
Figure 4  
1270x952mm (120 x 120 DPI)  
Page 46 of 62
The International Society of Nephrology (http://www.isn-online.org/site/cms)
Kidney International
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
Figure 5: iTRAQ identifies 4 proteins with altered levels in an EPS patient compared to a matched control. 
Four PD samples from patient G05072 (confirmed EPS) were matched with 4 PD samples from patient G05
068 (stable membrane function), by time to finishing dialysis.  Each sample was precipitated in 3 volumes of 
acetone/10% TCA, redissolved & then buffer exchanged into triethylammonium bicarbonate (TEAB).  50 g 
of protein was denatured in tris(2carboxyethyl)phosphine and reduced in methylmethanethiosulfonate 
prior to trypsin digestion.  Each sample was then labelled with a different isobariq tag using the 8 label 
iTRAQ system.  All samples were mixed, fractionated by RPHPLC and proteins identified by MODITOF 
MS.  For each of 72 proteins detected, the ratio of each protein was calculated based on the abundance of 
each isobariq tag within that protein sample.  Using this approach 4 proteins showed consistent 
trends.  Orosomucoid1 and 2HSglycoprotein chain B were both elevated in the EPS patient some 12 
months before diagnosis, while Apolipoprotein AIV was always low in EPS with a dramatic late drop in 
serotransferrin.  Data shown represents fold change in the confirmed EPS patient compared to the patient 
with stable membrane function and is from a single experimental run.  
Figure 5  
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Figure 6: ProteoMiner™ allows detection of lower abundance proteins in PD fluid  
A PD fluid volume equivalent to 15mg of protein was reduced to 500µl volume using a 3kDa molecular 
weight cut off concentrator.  10mg of protein was then subjected to the low abundance protein enrichment 
using the Bio-Rad ProteoMiner™ system using 20µl of beads.  100 µg of eluted protein and that from the 
original PD fluid samples was precipitated using 3 volume acetone/10% TCA and comparative analysis 
performed using 2D SDS PAGE proteomic analysis as in figure 1.  The total number of resolved protein spots 
was calculated using PDQUEST.  
Figure 6A, Figure 6B  
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Figure 7: In protein mined PD fluid Intelectin-1  (a) and dermatopontin (b) are elevated in EPS.  
From a Greek cohort of PD fluid samples (University of Patras), fluid was taken from 3 patients with 
suspected EPS (2 of them confirmed post-portem), 3 patients who had remained on PD for more than 5 
years but had no signs of EPS (late controls) and 3 patients with samples taken within the first month of 
starting PD (early controls).  A volume equivalent to 15mg of protein was concentrated and subjected to 
ProteoMiner™ enrichment as in figure 6.  Samples were then subjected to 2D SDS-PAGE analysis as in figure 
1, with spots identified as different between the EPS (column 1), late controls (column 2) and early controls 
(column 3) identified using PDQUEST.  Spot 7203 (a) was identified as being elevated in all 3 patients with 
EPS, which was confirmed by subsequent volume densitometry measurement of the spot in all 9 
samples.  Spot 1001 (b) was identified as being elevated in all 3 patients with EPS and one of the late 
controls, which was confirmed by subsequent volume densitometry measurement of the spot in all 9 
samples.  These spots were subsequently excised from the gel and identified by MALDI-TOF as intelectin-1 
(a) and Dermatopontin (b).  Spot volume densitometry from all 3 patients in each group was averaged with 
data presented as mean±SEM in the 2 bar graphs.  Significance was determined by 1 way ANOVA, * 
p<0.05, ** p<0.01 compared to early PD control group.  
Figure 7a, Figure 7b  
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Figure 8: Analysis of pooled samples at four matched time-points using iTRAQ after treatment with 
Proteominer™.  
Patient samples were pooled into 4 groups based on time (>24 mths, 12-24 mths, 6-12 mths , <6 mths) to 
developing EPS or stopping PD.  Each pool consisted of equal amounts of protein from each sample 
available. Post pooling they were processed using ProteoMiner™, iTRAQ labelled, fractionated by RP HPLC 
and then subjected to tandem MS.    
Figure 8  
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Figure 9: Hierarchical Cluster analysis (a) and heatmap (b) of proteins detected from proteome-mined 
pooled EPS PD effluent iTRAQ analysis.  
The relative contribution of each pooled cohort to the total level of each protein identified was made based 
on the abundance of each isobariq tag.  The proteins detected in each cohort were then used to position 
each as a hierarchical cluster. E=EPS, N=Normal (stable PD), E1/N1 = >24 mths, E2/N2 = 12-24, E3/N3 = 
6-12 mths and E4/N4= <6Mths to EPS or stopping PD (a). The variation in each protein detected in each 
cohort was then plotted as a heat map (b). Arrows indicate Intellectin-1 and Gelsolin. Data is from a single 
run.  
Figure 9a, Figure 9b  
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Figure 10: Relative changes in proteins showing progressive variation with time in pooled cohorts of EPS 
patients subjected to protein mining and ITRAQ analysis.  
Relative levels of intelectin-1, Gelsolin, Apolipoprotein A-II and Heamaglobin beta subunit were determined 
by calculating the ratio to the >24-month cohort level in the patients not developing EPS.  Data represents 
ratio to >24month stable patient from a single run of pooled samples.  
Figure 10  
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Serum albumin Zinc-alpha-2-glycoprotein (Zn-alpha-2-glycoprotein)  
Serotransferrin (Transferrin) Beta-2-microglobulin form pI 5.3 
cDNA FLJ78387 Ig gamma-2 chain C region
Short peptide from AAT (SPAAT) Fibrinopeptide A 
Haptoglobin beta chain Alpha-1B-glycoprotein 
Fibrinogen alpha chain, isoform CRA_c Alpha-1-acid glycoprotein 2 (AGP 2) (OMD 2) 
Apolipoprotein A-I(1-242) Complement component 4A (Rodgers blood group)
Cyclosporin A transporter 1 cDNA FLJ53691, highly similar to Serotransferrin
Trypstatin Fibrinogen beta chain, isoform CRA_e
Apolipoprotein A-IV (Apo-AIV) (ApoA-IV) Low molecular weight growth-promoting factor 
Alpha-1-acid glycoprotein 1 (AGP 1) (OMD 1) Alpha-2-HS-glycoprotein chain B 
Complement C3c alpha' chain fragment 2 Complement factor H 
Ig gamma-3 chain C region LVV-hemorphin-7 
Ig alpha-1 chain C region cDNA FLJ51265, similar to Beta-2-glycoprotein 1 
Alpha-2-HS-glycoprotein chain B Putative uncharacterized protein AZGP1
Hemopexin Complement factor B Bb fragment 
Alpha-1-antichymotrypsin His-Pro-less Ig kappa chain V-III region NG9 
Fibrinogen gamma chain, isoform CRA_a Leucine-rich alpha-2-glycoprotein (LRG) 
Alpha-2-macroglobulin (Alpha-2-M) Ig kappa chain V-III region CLL 
Ig kappa chain C region Histidine-rich glycoprotein, isoform CRA_a
Transthyretin Cystatin-C 
HCG1778670 Complement component C9b 
Retinol binding protein 4, plasma, isoform CRA_a Myosin-reactive immunoglobulin heavy chain variable region
cDNA FLJ53327, highly similar to Gelsolin Complement factor D 
Ig kappa chain V-I region EU
Table 1: Proteins detectable by iTRAQ in whole proteome PD f
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Vitamin D-binding protein (DBP) (VDB) 
Antithrombin
Cryocrystalglobulin CC1 kappa light chain variable region
Cryocrystalglobulin CC2 lambda light chain variable region
cDNA FLJ37971 fis, clone CTONG2009958, highly similar to 
CERULOPLASMIN (EC 1.16.3.1)
cDNA FLJ39644 fis, clone SMINT2004037, highly similar to CHLORIDE 
CHANNEL PROTEIN 7
cDNA FLJ52255, highly similar to Angiotensinogen
Thrombin heavy chain [CHAIN 1]
Apolipoprotein C-III (Apo-CIII) (ApoC-III) 
Ugl-Y3 
Inter-alpha-trypsin inhibitor heavy chain H1 (Inter-alpha-inhibitor heavy chain 
1) (ITI heavy chain H1) (ITI-HC1) (SHAP) 
Prostaglandin-H2 D-isomerase (PGD2 synthase) (PGDS2) (PGDS) 
IGL@ protein
Nuclear fragile X mental retardation-interacting protein 2 (82-FIP)
Full-length cDNA clone CS0DD006YL02 of Neuroblastoma of Homo sapiens 
(human)
Zinc finger protein 527
Uncharacterized protein C7orf62
Kelch-like protein 3 [ISOFORM C]
Myosin-reactive immunoglobulin light chain variable region
ome PD fluid
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2D Gel 2D Gel ITRAQ ITRAQ
FP MP FP MP
gActin ­
Collaen( 
1) 1
­
1 
antitrypsin 
¯ ¯
-2-HS-
lycoprotein 
B
­ ­
Serotransfer
rin
­
Complement 
C4B
­
Complement 
B
­ ­
Complement 
I
­ ­
Apolipoprot
ein A-IV
¯ ¯ ¯
Orosomucoi
d-1
­ ­
Intelectin-1 ­ ­
Dermatopon
tin
­
RBP-4 ­
Gelsolin ­
Haemalobi
n b
­
Apolipoprot
ein A-II
¯
Chane in EPS PDE
Table 2: Top potential hits for EPS bio markers fro
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6/6 patients ( early./ elevated >3 yrs before EPS)
6/6 patients (early / > 3 yrs before EPS)
3/6 patients plus iTRAQ  (slow reduction  with time -v low at EPS) 
NA.  ( mid/  6 -12 months before EPS)
NA   ( early /  > 12 months before EPS)
NA    ( early / > 12 months before EPS)
 5/6 patients  (early/elevated upto 6 years before EPS
5/6 patients (early /elevated up to 6 years before EPS
3/6 plus iTRAQ ( late / from 12 months . -80%  at EPS)
NA. (Early / > 1 yr before EPS)
3/3 patients & pooled  (late/within 6 months of EPS)
3/3 patients  (unknown)
3/3 patients   (unknown)
Pooled. (Mid / elevated up to 1 year before EPS)
Pooled (late / elevated up to 12  months before EPS)
Pooled ( late/ low for up to 12 mths before EPS
Frequency of occurrence in 2D gels  (times of change)
arkers from 2D PAGE & iTRAQ proteomics  
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EPS Control EPS Control EPS Control 
(6 patients, 33 
samples)
(6 patients, 33 
samples)
 (5 patients, 5 
samples)
 (6 patients, 6 
samples)
(5 patients, 5 
samples)
(5 patients, 5 
samples)
Age (years) 54.8 (15.4) 51.8 (16.5) 45.6 (12.4) 55.0 (14.4) 48.5 (16.3) 54.3 (11.2)
Male Gender 66.70% 66.70% 60% 17% 40% 60%
Comorbidity 
(Low/Medium
/High)
50.0/50.0/0% 50/33.3/16.7% 60.0/40.0/0% 50.0/33.3/16.7% 60.0/40.0/0% 60.0/0/40.0%
Previous 
peritonitis 
episodes
0 (0-4) 1 (0-4) 1 (0-6) 2 (0-6) 2 (0-5) 2 (0-3)
Months From 
PD Start
35.2 (26.0) 33.9 (25.2) 55.1 (24.8) 72.4 (51.2) 73.3 (44.2) 42.6 (15.8)
Months Until 
PD End
29.5 (21.9) 30.4 (16.7) 1.8 (3.5) 1.8 (0.6) 8.9 (2.2) 8.8 (2.3)
Urine volume 
(mls)
663 (0-2128) 816 (0-2092) 60 (0-120) 0 (0-940) 170 (0-1322) 120 (0-1508)
Icodextrin 
Usage
36.40% 26.50% 40% 66.70% 20% 24%
APD usage 21.20% 30.30% 60.00% 80.00% 40% 80%
Dialysate IL-6 
(pg/ml)
13.9 (0.1-
134.2)
7.0 (0.0-87.8)
75.9 (24.1-
134.2)
24.8 (10.1-
45.1)
10.7 (2.7-79.8) 12.9 (2.4-52.9)
Plasma IL-6 
(pg/ml)
3.8 (0.5-54.7) 1.1 (0.2-4.0) 3.9 (0.7-11.1) 4.1 (0.6-8.8) 3.3 (0.9-9.6) 4.2 (4.1-13.9)
Serum 
Albumin (g/L)
33.9 (8.2) 36.9 (4.7) 30.0 (10.2) 33.4 (5.5) 35.0 (5.2) 35.8 (3.6)
D/P Cr 0.72 (0.14) 0.69 (0.12) 0.88 (0.08) 0.89 (0.15) 0.92 (0.19) 0.81 (0.14)
2D Gels
iTRAQ pooled samples
Group 1 Group 2
Table 3a: Global Fluid Study cohort - Demographic Data
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EPS Control EPS Control 
(5 patients, 5 
samples)
(6 patients, 6 
samples)
(5 patients, 6 
samples)
(7 patients, 7 
samples)
48.8 (17.0) 53.1 (18.4) 47.4 (20.8) 60.5 (19.8)
80% 83.00% 40% 71%
40.0/60.0/0% 33.3/50.0/16.7% 40.0/60.0/0% 57.1/42.9/0%
1 (0-4) 2 (0-4) 0.5 (0-2) 1 (0-4)
38.6 (29.4) 31.5 (17.6) 30.1 (24.6) 32.8 (22.4)
15.5 (8.9) 15.6 (2.0) 47.9 (11.9) 47.9 (8.6)
295 (0-1570) 604 (0-1160) 550 (0-2004) 1216 (0-1305)
60.00% 68.20% 33.30% 79.20%
40% 66.60% 0% 0.00%
14.6 (7.7-
1902.9)
42.5 (0.7-
116.1)
10.2 (4.6-45.1) 4.3 (2.9-13.8)
4.4 (0.5-31.2) 2.0 (0.6-12.6) 3.4 (0.9-10.1) 1.0 (0.0-5.4)
29.8 (10.6) 35.7 (4.7) 33.3 (9.2) 38.8 (3.9)
0.74 (0.12) 0.83 (0.08) 0.70 (0.14) 0.64 (0.09)
iTRAQ pooled samples
Group 3 Group 4
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EPS Controls New starters
(n=3) (n=3) (n=3)
Age (years) 59 (30-64) 56 (50-80) 45 (43-60)
Male Gender 67% 33% 33%
Comorbidity 
(Low/Medium/High)
67/0/33% 67/33/0% 33/67/0%
Previous peritonitis episodes 1 (0-4) 0 0
Months From PD Start 108 (61-178) 85 (68-97) <1
Urine volume (mls) 0 (0-200) 800 (500-1000) 1000 (600-1700)
Icodextrin Usage 67% 33% 0%
APD usage 33% 33% 33%
Serum Albumin (g/L) 32 (29-33) 34 (32-38) 40 (36-40)
D/P Cr 0.89 (0.74-0.91) 0.62 (0.58-0.76) 0.72 (0.67-0.73)
Table 3b: University of Patras cohort - Demographic Data
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